Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPIDe-3: Oral deucrictibant for on-demand treatment of hereditary angioedema attacks
jRCT2061240048Phase 3Active, not recruiting
- Sponsor
- Pharvaris
- Start
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of deucrictibant in hereditary angioedema (HAE) (2 arms), sponsored by Pharvaris. Primary endpoint: Time to onset of symptom relief. Started Oct 2024; status: active, not recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2061240048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240048.